Dersimelagon for previously untreated erythropoietic protoporphyria and X-linked protoporphyria

Dersimelagon is being developed for the treatment of erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP). EPP and XLP are rare diseases that cause intolerance to light. In
patients with EPP or XLP, exposure to light can lead to symptoms such as pain and swelling of the
skin, which prevent patients from being able to spend time outdoors or in places with bright light.
EPP and XLP are inherited diseases which are caused by genetic changes. The most common form
of preventing a reaction is to avoid exposure to sunlight.